Brief: Orgenesis Announces Collaboration Agreement With Savicell To License And Deploy Its ImmunoBiopsy Platform
23/08/2021 13:48
Aug 23 (Reuters) - Orgenesis Inc ORGS.O :
* ORGENESIS ANNOUNCES COLLABORATION AGREEMENT WITH SAVICELL
TO
LICENSE AND DEPLOY ITS IMMUNOBIOPSY™ PLATFORM
* ORGENESIS INC - PLAN TO DEVELOP COMPANION DIAGNOSTICS TO
ENHANCE
TARGETING OF CELL AND GENE THERAPIES
* ORGENESIS INC - NEW ASSAYS BEING DEVELOPED TO POTENTIALLY
ENHANCE POTENCY OF CELL AND GENE THERAPIES FOR USE WITHIN POCARE
PLATFORM
* ORGENESIS INC - UNDER AGREEMENT, CO WILL RECEIVE
WORLDWIDE,
EXCLUSIVE RIGHTS AND LICENSE TO USE AND SELL KITS PRODUCED BY
SAVICELL
Source text for Eikon: ID:nGNXc01JsK
Further company coverage: ORGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orgenesis
See all newsBrief: Orgenesis Nasdaq To Delist Co'S Common Stock, Securities Trading Will Be Suspended On Oct 21
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules